High-dose intravenous vitamin C combined with cytotoxic chemotherapy in patients with advanced cancer: A phase I-II clinical trial

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Hoffer, L John ^a   Robitaille, Line ^b   Zakarian, Robert ^b,c   Melnychuk, David ^b,c   Kavan, Petr ^b,c   Agulnik, Jason ^a,b   Cohen, Victor ^a,b,c   Small, David ^a,b   Miller, Wilson H ^b,c  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ASCORBIC ACID; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OXALIC ACID; OXALIPLATIN; PACLITAXEL; TAMOXIFEN; TRASTUZUMAB; ANTIOXIDANT;

ABDOMINAL DISCOMFORT; ADULT; ADVANCED CANCER; AGED; ARTICLE; BILIARY STENT; BILIARY TRACT CANCER; BLADDER CANCER; BLADDER CARCINOMA; BRACHYTHERAPY; BREAST CANCER; CANCER RADIOTHERAPY; CANCER SURGERY; CHEMORADIOTHERAPY; CHILL; CHOLECYSTOSTOMY; CLINICAL ARTICLE; COLON ADENOCARCINOMA; COLON CANCER; CONFUSION; CONTINUOUS INFUSION; CYSTECTOMY; DRUG BLOOD LEVEL; DRUG COMPETITION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXCRETION; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG UPTAKE; DRUG WITHDRAWAL; EPIGASTRIC DISCOMFORT; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FEMALE; FEVER; HEADACHE; HEMICOLECTOMY; HUMAN; HYPOTENSION; ILEAL CONDUIT; LEG EDEMA; LUNG ADENOCARCINOMA; LUNG CANCER; MALE; MAXIMUM PLASMA CONCENTRATION; MENTAL DEFICIENCY; MIDDLE AGED; MOOD; MULTIPLE CYCLE TREATMENT; NAUSEA; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHYSICAL DISABILITY; QUALITY OF LIFE; RECTUM CANCER; RECTUM CARCINOMA; SIDE EFFECT; SMALL CELL LUNG CANCER; THIRST; TONSIL CANCER; TONSIL CARCINOMA; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; VATER PAPILLA CARCINOMA; VOMITING; CASE REPORT; CLINICAL TRIAL; COMBINATION DRUG THERAPY; INTRAVENOUS DRUG ADMINISTRATION; MULTICENTER STUDY; NEOPLASMS; TISSUE DISTRIBUTION;

AGED; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; ASCORBIC ACID; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASMS; QUALITY OF LIFE; TISSUE DISTRIBUTION;

EID: 84928886560     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0120228     Document Type: Article

References (60)

1. Block KI, Mead MN. Vitamin C in alternative cancer treatment: historical background. Integ Cancer Ther 2003; 2:147-54. PMID: 15035902
2. Challem J, Gonzalez MJ, Levy TE, Hunninghake R, Matalon V. Roundtable: Intravenous Vitamin C for Treating Cancer. Alt Complement Ther 2009; 15:81-6.
3. Padayatty SJ, Sun AY, Chen Q, Espey MG, Drisko J, Levine M. Vitamin C: intravenous use by complementary and alternative medicine practitioners and adverse effects. PLoS ONE 2010. 5:e11414. doi: 10.1371/journal.pone.0011414 PMID: 20628650
4. Chen Q, Espey MG, Sun AY, Lee J, Krishna MC, Shacter E et al. Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proc Natl Acad Sci USA 2007; 104:8749-54. PMID: 17502596
5. Yeom CH, Lee G, Park JH, Yu J, Park S, Yi SY et al. High dose concentration administration of ascorbic acid inhibits tumor growth in BALB/C mice implanted with sarcoma 180 cancer cells via the restriction of angiogenesis. J Transl Med 2009. 7:70. doi: 10.1186/1479-5876-7-70 PMID: 19671184
6. Verrax J, Calderon PB. Pharmacologic concentrations of ascorbate are achieved by parenteral administration and exhibit antitumoral effects. Free Rad Biol Med 2009; 47:32-40. doi: 10.1016/j.freeradbiomed.2009.02.016 PMID: 19254759
7. Levine M, Espey MG, Chen Q. Losing and finding a way at C: new promise for pharmacologic ascorbate in cancer treatment. Free Rad Biol Med 2009; 47:27-9. doi: 10.1016/j.freeradbiomed.2009.04.001 PMID: 19361554
8. Ohno S, Ohno Y, Suzuki N, Soma G, Inoue M. High-dose vitamin C (ascorbic acid) therapy in the treatment of patients with advanced cancer. Anticancer Res 2009; 29:809-15. PMID: 19414313
9. Takemura Y, Satoh M, Satoh K, Hamada H, Sekido Y, Kubota S. High dose of ascorbic acid induces cell death in mesothelioma cells. Biochem Biophys Res Commun 2010; 394:249-53. doi: 10.1016/j.bbrc.2010.02.012 PMID: 20171954
10. Pollard HB, Levine MA, Eidelman O, Pollard M. Pharmacological ascorbic acid suppresses syngeneic tumor growth and metastases in hormone-refractory prostate cancer. In Vivo 2010; 24:249-55. PMID: 20554995
11. Du J, Martin SM, Levine M, Wagner BA, Buettner GR, Wang SH et al. Mechanisms of ascorbate-induced cytotoxicity in pancreatic cancer. Clin Cancer Res 2010; 16:509-20. doi: 10.1158/1078-0432.CCR-09-1713 PMID: 20068072
12. Fromberg A, Gutsch D, Schulze D, Vollbracht C, Weiss G, Czubayko F et al. Ascorbate exerts anti-proliferative effects through cell cycle inhibition and sensitizes tumor cells towards cytostatic drugs. Cancer Chemother Pharmacol 2011; 67:1157-66. doi: 10.1007/s00280-010-1418-6 PMID: 20694726
13. Klingelhoeffer C, Kammerer U, Koospal M, Muhling B, Schneider M, Kapp M et al. Natural resistance to ascorbic acid induced oxidative stress is mainly mediated by catalase activity in human cancer cells and catalase-silencing sensitizes to oxidative stress. BMC Complement Altern Med 2012. 12:61. doi: 10.1186/1472-6882-12-61 PMID: 22551313
14. Putchala MC, Ramani P, Sherlin HJ, Premkumar P, Natesan A. Ascorbic acid and its pro-oxidant activity as a therapy for tumours of oral cavity: a systematic review. Arch Oral Biol 2013; 58:563-74. doi: 10.1016/j.archoralbio.2013.01.016 PMID: 23477602
15. Rawal M, Schroeder SR, Wagner BA, Cushing CM, Welsh JL, Button AM et al. Manganoporphyrins increase ascorbate-induced cytotoxicity by enhancing H2O2 generation. Cancer Res 2013; 73:5232-41. doi: 10.1158/0008-5472.CAN-13-0470 PMID: 23764544
16. Kawada H, Kaneko M, Sawanobori M, Uno T, Matsuzawa H, Nakamura Y et al. High concentrations of L-ascorbic acid specifically inhibit the growth of human leukemic cells via downregulation of HIF-1 transcription. PLoS ONE 2013. 8:e62717. doi: 10.1371/journal.pone.0062717 PMID: 23626851
17. Meadows GG, Pierson HF, Abdallah RM. Ascorbate in the treatment of experimental transplanted melanoma. Am J Clin Nutr 1991; 54:1284S-91S. PMID: 1962584
18. Sarna S, Bhola RK. Chemo-immunotherapeutical studies on Dalton's lymphoma in mice using cisplatin and ascorbic acid: synergistic antitumor effect in vivo and in vitro. Arch Immunol Ther Exp 1993; 41:327-33. PMID: 8010874
19. Chen Q, Espey MG, Sun AY, Pooput C, Kirk KL, Krishna MC et al. Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci USA 2008; 105:11105-9. doi: 10.1073/pnas.0804226105 PMID: 18678913
20. Espey MG, Chen P, Chalmers B, Drisko J, Sun AY, Levine M et al. Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer. Free Rad Biol Med 2011; 50:1610-9. doi: 10.1016/j.freeradbiomed.2011.03.007 PMID: 21402145
21. Monti DA, Mitchell E, Bazzan AJ, Littman S, Zabrecky G, Yeo CJ et al. Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. PLoS ONE 2012. 7:e29794. doi: 10.1371/journal.pone.0029794 PMID: 22272248
22. Welsh JL, Wagner BA, van't Erve TJ, Zehr PS, Berg DJ, Halfdanarson TR et al. Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial. Cancer Chemother Pharmacol 2013; 71:765-75. doi: 10.1007/s00280-013-2070-8 PMID: 23381814
23. Ma Y, Chapman J, Levine M, Polireddy K, Drisko J, Chen Q. High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. Sci Transl Med 2014. 6:222ra18. doi: 10.1126/scitranslmed.3007154 PMID: 24500406
24. Riordan HD, Casciari JJ, Gonzalez MJ, Riordan NH, Miranda-Massari JR, Taylor P et al. A pilot clinical study of continuous intravenous ascorbate in terminal cancer patients. P R Health Sci J 2005; 24:269-76. PMID: 16570523
25. Padayatty SJ, Riordan HD, Hewitt SM, Katz A, Hoffer LJ, Levine M. Intravenously administered vitamin C as cancer therapy: three cases. CMAJ 2006; 174:937-42. PMID: 16567755
26. Hoffer LJ, Levine M, Assouline S, Melnychuk D, Padayatty SJ, Rosadiuk K et al. Phase I clinical trial of intravenous ascorbic acid in advanced malignancy. Ann Oncol 2008; 19:1969-74. doi: 10.1093/annonc/mdn377 PMID: 18544557
27. Cabanillas F. Vitamin C and cancer: what can we conclude - 1,609 patients and 33 years later? P R Health Sci J 2010; 29:215-7. PMID: 20799507
28. Stephenson CM, Levin RD, Spector T, Lis CG. Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer. Cancer Chemother Pharmacol 2013; 72:139-46. doi: 10.1007/s00280-013-2179-9 PMID: 23670640
29. Fritz H, Flower G, Weeks L, Cooley K, Callachan M, McGowan J et al. Intravenous vitamin C and cancer: a systematic review. Integ Cancer Ther 2014:1-22. Published online 26 May 2014. doi: 10.1177/1534735414534463.
30. Doroshow JH. Redox modulation of chemotherapy-induced tumor cell killing and normal tissue toxicity. J Natl Cancer Inst 2006; 98:223-5. PMID: 16478735
31. Fang J, Nakamura H, Iyer AK. Tumor-targeted induction of oxystress for cancer therapy. J Drug Target 2007; 15:475-86. PMID: 17671894
32. Nakayama A, Alladin KP, Igbokwe O, White JD. Systematic review: generating evidence-based guidelines on the concurrent use of dietary antioxidants and chemotherapy or radiotherapy. Cancer Invest 2011; 29:655-67. doi: 10.3109/07357907.2011.626479 PMID: 22085269
33. Park JH, Davis KR, Lee G, Jung M, Jung Y, Park J et al. Ascorbic acid alleviates toxicity of paclitaxel without interfering with the anticancer efficacy in mice. Nutr Res 2012; 32:873-83. doi: 10.1016/j.nutres.2012.09.011 PMID: 23176798
34. Marcus SL, Petrylak DP, Dutcher JP, Paietta E, Ciobanu N, Strauman J et al. Hypovitaminosis C in patients treated with high-dose interleukin 2 and lymphokine-activated killer cells. Am J Clin Nutr 1991; 54:1292S-7S. PMID: 1962585
35. Weijl NI, Hopman GD, Wipkink-Bakker A, Lentjes EG, Berger HM, Cleton FJ et al. Cisplatin combination chemotherapy induces a fall in plasma antioxidants of cancer patients. Ann Oncol 1998; 9:1331-7. PMID: 9932164
36. Jonas CR, Puckett AB, Jones DP, Griffith DP, Szeszycki EE, Bergman GF et al. Plasma antioxidant status after high-dose chemotherapy: a randomized trial of parenteral nutrition in bone marrow transplantation patients. Am J Clin Nutr 2000; 72:181-9. PMID: 10871578
37. Wang Y, Liu XJ, Robitaille L, Eintracht S, Macnamara E, Hoffer LJ. Effects of vitamin C and vitamin D administration on mood and distress in acutely hospitalized patients. Am J Clin Nutr 2013; 98:705-11. doi: 10.3945/ajcn.112.056366 PMID: 23885048
38. Storer BE. Design and analysis of phase I clinical trials. Biometrics 1989; 45:925-37. PMID: 2790129
39. Perrone F, Di MM, De ME, Maione P, Ottaiano A, Pensabene M et al. Statistical design in phase II clinical trials and its application in breast cancer. Lancet Oncology 2003; 4:305-11. PMID: 12732168
40. Brown SR, Gregory WM, Twelves CJ, Buyse M, Collinson F, Parmar M et al. Designing phase II trials in cancer: a systematic review and guidance. Br J Cancer 2011; 105:194-9. doi: 10.1038/bjc.2011.235 PMID: 21712822
41. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-47. doi: 10.1016/j.ejca.2008.10.026 PMID: 19097774
42. Trotti A, Colevas AD, Setser A, Basch E. Patient-reported outcomes and the evolution of adverse event reporting in oncology. J Clin Oncol 2007; 25:5121-7. PMID: 17991931
43. Riordan NH, Riordan HD, Meng X, Li Y, Jackson JA. Intravenous ascorbate as a tumor cytotoxic chemotherapeutic agent. Medical Hypotheses 1995; 44:207-13. PMID: 7609676
44. Riordan HD, Hunninghake RB, Riordan NH, Jackson JJ, Meng X, Taylor P et al. Intravenous ascorbic acid: protocol for its application and use. P R Health Sci J 2003; 22:287-90. PMID: 14619456
45. Robitaille L, Mamer OA, Miller WH Jr., Levine M, Assouline S, Melnychuk D et al. Oxalic acid excretion after intravenous ascorbic acid administration. Metabolism 2009; 58:263-9. doi: 10.1016/j.metabol.2008.09.023 PMID: 19154961
46. Ho J, Pond GR, Newman C, Maclean M, Chen EX, Oza AM et al. Barriers in phase I cancer clinical trials referrals and enrollment: five-year experience at the Princess Margaret Hospital. BMC Cancer 2006. 6:263. PMID: 17092349
47. Mills EJ, Seely D, Rachlis B, Griffith L, Wu P, Wilson K et al. Barriers to participation in clinical trials of cancer: a meta-analysis and systematic review of patient-reported factors. Lancet Oncology 2006; 7:141-8. PMID: 16455478
48. Weeks L, Balneaves LG, Paterson C, Verhoef M. Decision-making about complementary and alternative medicine by cancer patients: integrative literature review. Open Med 2014; 8:e54-e66. PMID: 25009685
49. Vasudevan S, Hirsch IB. Interference of intravenous vitamin C with blood glucose testing. Diabetes Care 2014; 37:e93-e94. doi: 10.2337/dc13-2452 PMID: 24757251
50. Ma Y, Sullivan GG, Schrick E, Choi IY, He Z, Lierman J et al. A convenient method for measuring blood ascorbate concentrations in patients receiving high-dose intravenous ascorbate. J Am Coll Nutr 2013; 32:187-93. doi: 10.1080/07315724.2013.791167 PMID: 23885992
51. Yeom CH, Jung GC, Song KJ. Changes of terminal cancer patients' health-related quality of life after high dose vitamin C administration. J Korean Med Sci 2007; 22:7-11. PMID: 17297243
52. Vollbracht C, Schneider B, Leendert V, Weiss G, Auerbach L, Beuth J. Intravenous vitamin C administration improves quality of life in breast cancer patients during chemo-/radiotherapy and aftercare: results of a retrospective, multicentre, epidemiological cohort study in Germany. In Vivo 2011; 25:983-90. PMID: 22021693
53. Takahashi H, Mizuno H, Yanagisawa A. High-dose intravenous vitamin C improves quality of life in cancer patients. Personalized Med Universe 2012; 1:49-53.
54. Suh SY, Bae WK, Ahn HY, Choi SE, Jung GC, Yeom CH. Intravenous vitamin C administration reduces fatigue in office workers: a double-blind randomized controlled trial. Nutr J 2012. 11:7. doi: 10.1186/1475-2891-11-7 PMID: 22264303
55. Block KI, Koch AC, Mead MN, Tothy PK, Newman RA, Gyllenhaal C. Impact of antioxidant supplementation on chemotherapeutic efficacy: a systematic review of the evidence from randomized clinical trials. Cancer Treatment Rev 2007; 33:407-18. PMID: 17367938
56. Block KI, Koch AC, Mead MN, Tothy PK, Newman RA, Gyllenhaal C. Impact of antioxidant supplementation on chemotherapeutic toxicity: a systematic review of the evidence from randomized controlled trials. Int J Cancer 2008; 123:1227-39. doi: 10.1002/ijc.23754 PMID: 18623084
57. Parrow NL, Leshin JA, Levine M. Parenteral ascorbate as a cancer therapeutic: a reassessment based on pharmacokinetics. Antioxid Redox Signal 2013; 19:2141-56. doi: 10.1089/ars.2013.5372 PMID: 23621620
58. Drazen JM, Gelijns AC. Statin strikeout. N Engl J Med 2014; 370:2240-1. doi: 10.1056/NEJMe1405032 PMID: 24835850
59. Mailankody S, Prasad V. Comparative effectiveness questions in oncology. N Engl J Med 2014; 370:1478-81. doi: 10.1056/NEJMp1400104 PMID: 24738667
60. Schwartz L, Buhler L, Icard P, Lincet H, Steyaert JM. Metabolic treatment of cancer: intermediate results of a prospective case series. Anticancer Res 2014; 34:973-80. PMID: 24511042